Overview

A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus

Status:
Completed
Trial end date:
2008-12-18
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to look at concentrations of GSK189075 in blood when single doses of the drug are taken by mouth in combination with basal insulin. The clinical effects of the drug in combination with insulin on the body will also be studied. The results will help determine doses of GSK189075 can be studied in the future in the type I diabetes mellitus population.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline